How could Roche terminating Ionis's Huntington's drug program affect Novartis?
Novartis's rights to Ionis drugs may face reduced commercial value The termination of the Huntington's drug program by Roche, alongside other clinical failures and financial strain, raises questions about the overall development trajectory of Ionis Pharmaceuticals. Since Novartis holds global rights from Ionis for the joint development and commercialization of advanced experimental drugs, increased uncertainty regarding Ionis's pipeline could potentially reduce the perceived commercial value of those assets. This risk is compounded by Ionis's reported financial decline, including a roughly 41% year-over-year revenue drop in the second quarter of 2026.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches Novartis
-
Roche terminated the drug development partnership it held with Ionis Pharmaceuticals. This decision follows other clinical setbacks for Ionis, including the failure of Eplontersen to meet its primary endpoint in a Phase 3 study for treating transthyretin amyloid cardiomyopathy.
The full event1independent outlet -
The combination of clinical setbacks and financial pressure, including Ionis's second-quarter 2026 revenue decline of roughly 41% to $268 million, suggests increased risk in Ionis's overall pipeline. Since Novartis holds global rights from Ionis for advanced experimental drugs, this increased uncertainty could affect the commercial valuation of those assets.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
Swiss-American multinational pharmaceutical corporation
Everything about Novartis
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Roche threw in the towel on a Huntington's disease drug developed by Ionis.fool.com
- Ionis experienced two clinical setbacks on July 9, 2026.fool.com
- Eplontersen failed to meet its primary endpoint in a Phase 3 study for treating transthyretin amyloid cardiomyopathy (ATTR-CM).fool.com
- Ionis' revenue declined by roughly 41% year over year in the second quarter of 2026 to $268 million.fool.com
Why it matters
Novartis's investment in Ionis's advanced experimental drugs relies on the perceived success and stability of Ionis's overall pipeline. If the market views Ionis as having a higher risk profile due to multiple clinical failures and financial struggles, the potential commercial returns for Novartis's licensed assets could be diminished.
Ionis Pharmaceuticals is a key partner to Novartis, holding joint development and commercialization rights for several advanced drugs. The termination of a major program like the Huntington's drug, coupled with other recent failures, contributes to a broader narrative of development challenges for the company.
What we don't know yet
- Will Novartis seek to renegotiate the terms of its rights with Ionis Pharmaceuticals?
- How will the market react to Ionis's financial performance in subsequent quarters?
What would change this answer
— Other considerations
Beyond this explainer
Explore connected ideas
Each opens a map of what the web connects to it, with Brind's news on it.
The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.
Who else could feel it
Other possible ripples from the same event.
Reporting
- fool.comSaturday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.